Debut, a U.S. based beauty biotech company, invested $20 million to accelerate its platform that uses AI to screen upward of 50 billion ingredients, exploring the 99.999% of unknown molecules that can optimize skin health and longevity. This would allow the company to predict the efficacy of ingredients and scale the formulations in the U.S. and Asia.
Debut, a U.S. based beauty biotech company, invested $20 million to accelerate its platform that uses AI to screen upward of 50 billion ingredients, exploring the 99.999% of unknown molecules that can optimize skin health and longevity. This would allow the company to predict the efficacy of ingredients and scale the formulations in the U.S. and Asia.
In January, Debut launched the AI platform, BeautyORB, leading the biotech company to uncover three clinically tested and bio-based ingredients. In wake of this launch and now a new investment to take it further, predictive capabilities of Debut's skin health datasets recently surpassed publicly available datasets, per an August 26 press release, achieving 99% data consistency.
"AI combined with an understanding of skin biology enables the creation of custom formulation solutions for different geographies that has previously not been possible," said Joshua Britton, PhD, founder and CEO of Debut.
The three ingredients BeautyORB was able to discover included DermCeutical InflammagePRO for inflammaging, DermCeutical Barrier RepairPRO for epidermal barrier repair and DermCeutical LongevityPRO for cellular longevity.
The January 28 press release claims that BeautyORB will create two biotech ingredients each year, and the investment builds on and facilitates this progress—giving other beauty brands access to clinical claims and product innovation.
“With our advanced AI platform and understanding of skin biology, we can rapidly create brand new ingredients through computational compound prediction,” Britton said. “This allows us to activate specific aspects of skin biology while also discovering new or improved cellular pathways for enhanced clinical claims.”
